Abstract: One method for estimating the extracorporeal blood volume in a portion of a physical sample includes: extracting a feature from a portion of an image of the sample; tagging the portion of the image of the sample with a blood volume indicator according to the extracted feature; and estimating the extracorporeal blood volume in at least the portion of the physical sample, associated with the portion of the image of the sample, according to the blood volume indicator.

Abstract: Techniques and apparatuses for access recirculation of a patient during dialysis treatment are described. In one embodiment, for example, an apparatus may include at least one memory, and logic coupled to the at least one memory. The logic may be configured to determine a first hemoglobin concentration for a dialysis system, determine a change in an ultrafiltration rate, determine a second hemoglobin concentration modified due to the change in the ultrafiltration rate based on a dialysis system model of the dialysis system, and determine an access recirculation value for the dialysis system. Other embodiments are described.

Abstract: An infusion pump system and method provide concurrent infusion with common line auto flush. The infusion pump system has a first reservoir, a second reservoir, a junction, a mixing chamber, a common line having one end in fluid connection with the mixing chamber and having a terminal fluid delivery end, and an infusion pump. The method includes infusing the first fluid at a first rate along a first flow path; determining a common line flush volume value for the common line; switching to a concurrent infusion mode to drive a combination of the first fluid and the second fluid at the first rate along a second flow path including the common line; monitoring a volume of the combination of the first and second fluids driven at the first rate; and driving the combination of the first and second fluids at a combined rate along the second flow path when the monitored volume is equal to or greater than the common line flush volume value.

Abstract: The present invention concerns an anticoagulation fluid comprising 10-40 mM citrate and 0.1-4 mM phosphate. The anticoagulation fluid is to be used for regional citrate anticoagulation in an extracorporeal blood circuit. The anticoagulation fluid may be combined with at least one treatment fluid in a dialysis treatment, and it may be included in a system for regional citrate anticoagulation in an extracorporeal blood circuit.

Abstract: An apparatus configured to quantify and display a time buffer for at least one patient during a blood treatment session is described. A blood treatment apparatus which includes such an apparatus or is in signal communication therewith, and a method for quantifying and presenting the time buffer for at least one patient at a blood treatment session are also described, as well as a computer program, a computer program product and a digital storage medium.

Abstract: A fully-automatic regional citrate anticoagulation machine is disclosed. A sampling portion extracts a blood sample on line and in real time and sends it to a storage purifier for storage and purification. A sample injection portion conveys the blood sample in the blood sample storage purifier to a sample loading slot through a sample injection tube. An assay and analysis portion conveys, through a sample suction tube, the blood sample to an analyzer for blood sample assay and analysis. The sampling portion, the sample injection portion, the assay and analysis portion and an administration portion are connected to the program control portion. The program control portion controls, according to an internally-set program, operation of the sampling portion, the sample injection portion and the assay and analysis portion, and sends an instruction to the administration portion according to the data result obtained by the assay and analysis portion.

Abstract: The present invention concerns a multipart fluid system for dialysis therapy, wherein the multipart fluid system comprises an anticoagulation fluid and at least one treatment fluid from the group consisting of dialysis fluid and infusion fluids. According to the invention the anticoagulation fluid comprises 15-40 mM citrate; and the at least one treatment fluid comprises 1.5-8 mM citrate and ?10 mM bicarbonate. The present invention further concerns a system for citrate anticoagulation in an extracorporeal blood circuit.

Abstract: The present invention relates to an acid concentrate dialysis composition comprising a mixture of citric acid and citrate, having pH of less than 3.0, wherein the total concentration of citrate is between 35 mM and 450 mM, and wherein the amount of citric acid is more than 50% of the total concentration of citrate. The acid concentrate dialysis composition is to be combined to form a dialysis solution having a total concentration of citrate of between 1 and 6 mM.

Abstract: The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.

Abstract: An apparatus for the extracorporeal treatment of blood comprising an extracorporeal blood circuit (2), a pump (6) configured to provide fluid displacement within the extracorporeal blood circuit, and a reaction chamber (8) connected to the extracorporeal blood circuit and configured to receive blood or plasma from the circuit and treat the blood or plasma. The reaction chamber comprises an protease enzyme immobilized to a support, in which the protease enzyme is specific for, and capable of irreversibly cleaving, a human C5a present in the blood or plasma, wherein the abundance of the human C5a in the treated blood or plasma is less than that in the untreated blood or plasma. The apparatus finds utility in the extracorporeal treatment of blood from patients with inflammatory conditions, especially auto-immune disease and sepsis.

Abstract: The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.

Abstract: An apparatus for extracorporeal blood treatment including a treatment unit; an extracorporeal blood circuit; an infusion line of a replacement fluid; a dialysis line connected in inlet to the second chamber; a fluid evacuation line; sensors for determining a first parameter relating to a patient's blood volume (BV %), a second parameter relating to an ultrafiltration flow rate (UFR) or to a patient's weight loss rate (WLR), a third parameter (Cd, Na) relating to a conductivity or concentration of a liquid crossing the dialysis line and/or the infusion line, and a fourth parameter relating to an infusion flow rate (QINF), and a control unit performing a control procedure to determine a variation in blood volume (BV %) and perform a setting sequence, wherein the control unit regulates a transmembrane pressure (TMP) to values which enable maximizing the convective exchanges.

Abstract: A renal failure therapy system includes a blood pump, a dialysis fluid pump, a filtrate pump, at least one infusion pump, and a control unit configured to synchronize operation of the infusion pump to the blood pump or the filtrate pump.

Abstract: A renal failure therapy system includes a blood circuit with a blood pump and a drug delivery pump. A control unit is operable with the blood pump and the drug delivery pump to control the drug delivery pump based upon the status of the blood pump.

Abstract: A system or method automates and optimizes citrate anticoagulant supplementation in a blood filtration circuit during CRRT. A processor-based control system interfaces with a blood filtration circuit to detect patient blood flow into the circuit, detect fluid loss through a hemofilter, and sense vital electrolyte concentrations in the blood flow, and in response, control the addition of citrate, substitution fluid, and electrolyte supplements to ensure stability of plasma concentrations in post-dilution flow returned to the patient. The controller executes the method embodied as process control algorithms for calculating an optimal citrate flow rate as a function of selected, detected, and calculated system parameters. Citrate may be added to the circuit separately, or as part of a substitution solution or a dialysate.

Abstract: A system or method automates and optimizes citrate anticoagulant supplementation in a blood filtration circuit during CRRT. A processor-based control system interfaces with a blood filtration circuit to detect patient blood flow into the circuit, detect fluid loss through a hemofilter, and sense vital electrolyte concentrations in the blood flow, and in response, control the addition of citrate, substitution fluid, and electrolyte supplements to ensure stability of plasma concentrations in post-dilution flow returned to the patient. The controller executes the method embodied as process control algorithms for calculating an optimal citrate flow rate as a function of selected, detected, and calculated system parameters. Citrate may be added to the circuit separately, or as part of a substitution solution or a dialysate.

Abstract: A method for increasing the shelf life of donor blood contemplates the following steps. In the first step blood is transferred to a sterile container and mixed with an anticoagulant as indicated in step 20. The anticoagulant and donor blood are centrifuged in step 22 at about 4,000 rpm for about 15 minutes. After centrifuging the red blood cells are separated and placed in a sterile tube. In the next step the red blood cells are irradiated by a laser that emanates a wavelength of about 633 nm for a time period of about 24 hours. During rotation the RBCs are rotated to provide uniform exposure. Such laser biostimulation produces an enhancement of shelf life of donor blood by 66%.

Abstract: The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.

Abstract: The present invention concerns a multipart fluid system for use in CRRT, wherein the multipart fluid system comprises an anticoagulation fluid and at least one fluid from the group consisting of a dialysis fluid and an infusion fluid. According to the invention the anticoagulation fluid comprises at least 8 mM citrate, and the dialysis fluid and/or infusion fluid comprises 2-8 mM citrate and 1-5 mM total calcium. The present invention further concerns a system for regional citrate anticoagulation in an extracorporeal blood circuit.

Abstract: Systems and methods are provided for automatically adjusting the operational parameters of a blood separation procedure. A blood separation device has an inlet for passing fluid thereinto and an outlet for removing fluid therefrom. A pump system is provided for moving fluid into and out of the device. In use, blood is conveyed into the device, where platelets are separated from at least a portion of the blood. A controller determines the amount of platelets in the device. Based at least in part on the amount of platelets in the device, corrective action is taken to avoid platelet aggregation in the device. The corrective action may be conveying an elevated amount of anticoagulant into the blood and/or the device and may be initiated when the determined amount of platelets approaches, meets, or exceeds a threshold predicted likelihood of platelet aggregation.

Abstract: A method of performing regional citrate anticoagulant dialysis of a patient's blood includes flowing blood from and back to the patient through an extracorporeal circuit including a dialyzer having semi-permeable dialysis membranes and a dialysate chamber surrounding the membranes. The method further includes flowing a dialysate containing calcium and citrate through the dialysate chamber of the dialyzer and introducing citrate into the patient's blood upstream of the dialyzer, whereby the patient's blood is dialyzed. The method can further include predicting the concentration of systemic ionized calcium in the blood of the patient at any point in the dialysis treatment or post-dialysis, such as by a mathematical model. The method can further include statistically correcting the preliminary predicted post-dialysis concentration of systemic ionized calcium in the patient's blood to provide a final predicted post-dialysis systemic ionized calcium concentration.

Abstract: A method for the re-anticoagulation of platelet rich plasma in a blood apheresis system includes priming the blood apheresis system with anticoagulant, such that a volume of anticoagulant is transferred to a PRP container. The method may then transfer the anticoagulant within the PRP container to a red blood cell container, and collect a volume of platelet rich plasma within the PRP container. The platelet rich plasma may be collected in a plurality of cycles. Between collection cycles, the method may transfer a portion of the volume of anticoagulant from the red blood cell container to the PRP container.

Abstract: A method and apparatus for collecting plasma reduced platelets potentially suspended in a synthetic solution from a donor. Whole blood is drawn from the donor and introduced into a separation chamber. Platelets are extracted from the separation chamber into a container, using, for example, surge (with anticoagulated plasma or a synthetic solution) or push methodologies. The remaining blood components in the separation chamber are returned back to the donor. The steps of drawing whole blood and introducing the whole blood into the separation chamber, extracting platelets from the separation chamber into the container, and returning the remaining components in the chamber back to the donor are repeated. The sequestered platelets in the container are reintroduced into the separation chamber, whereupon a plasma reduced platelet product is extracted.

Abstract: The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.

Abstract: A machine-readable medium with instructions for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.

Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

Abstract: The invention relates to a blood line (108) comprising an infusion site (145) intended to inject into the line a solution, comprising: —a first main channel (200) having a first passage section, —a second main channel (220) having a second passage section, —means for the formation (210) of a turbulence area located downstream from the first main channel, located upstream from the second main channel, these formation means comprising a first fluid passage means (224) defining a reduction (225) in the passage section and whose smallest passage section is smaller than the first passage section and smaller than the second fluid passage section, —a secondary channel (230) comprising an inlet (231) for letting in the solution and an outlet (232) in fluid communication with the first main channel or the means for the formation of a turbulence area or the second main channel.

Abstract: A method is provided for the filling of a metering apparatus of a therapy device having an extracorporeal circuit with which the metering apparatus is in communication such that an agent can be infused into the extracorporeal circuit during the operation of the therapy device by means of the metering device. The method includes a step of diluting a concentrate located in the metering apparatus by taking up a diluting agent from the extracorporeal circuit.

Abstract: A blood processing device includes a venous-access device, a blood component separation device, a return line, a draw line, a first pressure sensor, a second pressure sensor, and a first pump. The first pressure sensor is located on the return line between the blood component separation device and the venous-access device, and determines a first pressure. The second pressure sensor is located on the draw line between the blood component separation device and the venous-access device, and determines a second pressure. The first pump is connected to at least one of the return line and the draw line and controls a flow rate within the connected line based on a subject access pressure determined based upon the first and second pressures.

Abstract: A blood processing system for collecting and exchanging blood components includes a venous-access device for drawing whole blood from a subject and returning blood components to the subject. The system may also include three lines connecting the venous access device to a blood component separation device and an anticoagulant source. A blood draw line fluidly connects to the venous-access device to the blood component separation device. An anticoagulant line introduces anticoagulant into the drawn whole blood. A return line, fluidly connected to the venous-access device and the blood component separation device, and returns uncollected blood component to the subject. Each line may have a pump that controls flow through the line. The blood component separation device separates the drawn blood into a first blood component and a second blood component, and may be configured to send the first blood component to a first blood component bag.

Abstract: An extracorporeal blood processing method using a blood circuit comprising a pair of blood passages attached to opposite flow ends of a blood treatment device and said blood circuit is mounted on a blood pump console, the method includes: withdrawing blood from a vascular system of a human patient and drawing the blood into the blood circuit; pumping the withdrawn blood through one of the pair of blood passages using a first blood pump of the console and into the blood treatment device; pumping the treated blood from the treatment device through the other of the pair of blood passages using a second blood pump of the console; infusing the treated blood from the other blood passage and into the vascular system of the patient, and periodically reversing a flow direction of blood through the pair of blood passages and blood treatment device.

Abstract: A hemofiltration system and method for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.

Abstract: The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis.

Abstract: A method and apparatus for collecting plasma reduced platelets potentially suspended in a synthetic solution from a donor. Whole blood is drawn from the donor and introduced into a separation chamber. Platelets are extracted from the separation chamber into a container, using, for example, surge (with anticoagulated plasma or a synthetic solution) or push methodologies. The remaining blood components in the separation chamber are returned back to the donor. The steps of drawing whole blood and introducing the whole blood into the separation chamber, extracting platelets from the separation chamber into the container, and returning the remaining components in the chamber back to the donor are repeated. The sequestered platelets in the container are reintroduced into the separation chamber, whereupon a plasma reduced platelet product is extracted.

Abstract: This disclosure describes dialysis treatment monitoring systems and methods for operating dialysis treatment monitoring systems. The disclosure describes novel systems and methods for collecting and processing dialysis treatment information from a patient.

Abstract: This invention is directed to a method of collecting and separating whole blood into components. The method includes the steps of adding an anticoagulant having an acidic pH to a bag for collecting and/or separating whole blood, collecting whole blood in the bag, loading the bag containing anticoagulated whole blood on a rotor, spinning the bag on the rotor to separate the whole blood into at least one component; and squeezing the bag on the rotor to push the component from the separation bag into at least one satellite bag.

Abstract: The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.

Abstract: The invention provides a way of producing a natural immunologically active state in a person by subjecting him to an apheresis procedure with bioincompatible biomaterials for about one hour. To safely control the immunological shock induced by this procedure, the person is put under general anesthesia for about six hours, including the apheresis time and at least an additional five hours thereafter. This immunological activation is useful for treating malignant tumors and diseases related to immunosuppression, such as AIDS. The invention also provides for the use of an apheresis column containing a blood perfusion filter with bioincompatible materials for treating malignant tumors and infectious diseases.

Abstract: A system or method automates and optimizes citrate anticoagulant supplementation in a blood filtration circuit during CRRT. A processor-based control system interfaces with a blood filtration circuit to detect patient blood flow into the circuit, detect fluid loss through a hemofilter, and sense vital electrolyte concentrations in the blood flow, and in response, control the addition of citrate, substitution fluid, and electrolyte supplements to ensure stability of plasma concentrations in post-dilution flow returned to the patient. The controller executes the method embodied as process control algorithms for calculating an optimal citrate flow rate as a function of selected, detected, and calculated system parameters. Citrate may be added to the circuit separately, or as part of a substitution solution or a dialysate.

Abstract: A circuit for collecting a blood component includes a blood collection device provided with a blood collection needle through which blood is collected from a blood donor, a blood separator in which the blood collected by the above blood collection device is separated, a blood component collection bag in which a predetermined blood component separated by the above blood separator is collected, a blood line in which the blood collection needle is connected to an inlet of the blood separator, a line for removing an initial blood flow, which branches from a first branching portion formed in the blood line, and in which an initial flow of blood collected from the blood donor is removed, and an anticoagulant-injection line that branches from a second branching portion, formed in the line for removing the initial blood flow, and into which an anticoagulant is injected.

Abstract: A wound closure apparatus and associated methods are provided which utilize blood fluid by activating the clotting cascade of blood fluid within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. An apparatus for providing ways of inhibiting anticoagulating agents and slowing fibrin clot degradation are also disclosed. Kits are also disclosed. The invention provides a clotting cascade initiation apparatus including a substantially enclosed sterile containment chamber within which an aliquot of blood fluid, either autologous or from donor sources, can be received and retained. In preferred embodiments, the sterile containment chamber further includes a heparin binding agent which will bind heparin and remove it from the blood fluid. In further embodiments, the containment chamber will also include a procoagulating agent, wherein a clotting cascade can be initiated when the blood fluid is accepted into the sterile containment chamber.

Abstract: A switch comprises a rotating switch member which provides fluid communication in three modes; infusion, recirculation and priming The switch is located between the oxygenator and drug bag and the cardioplegia pump raceway. The switch has three channels molded into the rotating manifold which either direct blood and cardioplegia into the coronary arteries of the patient or into a recirculation line. When the switch is rotated into the recirculation line, a hose is in fluid connection through the switch and connects the recirculation line with the pump blood and drug inlet lines thereby allowing cooling of the cardioplegic mixture during the time between infusions.

Abstract: The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.

Abstract: An optical blood monitoring system with a ratiometric model determines hematocrit values for a hemodialysis patient, from which hemoglobin values for the patient are estimated. The ratiometric model is calibrated, normally against a cell counter, using blood from a blood bank. The blood from a blood bank is preserved in a long term preservative which is typically different than that found in clinical settings. The hematocrit value determined by the ratiometric model is scaled by scaling factor so that the estimated hemoglobin level output from the monitor consistently matches that measured in a clinical setting. The hematocrit scaling factor is substantially about 1.033 when the patient's blood sample is stored in a short term preservative ethylene diamine tetra acetic, and is substantially about 1.06 when the hematocrit is measured in the blood sample without preservative being added to the blood sample. The hemoglobin value can also be adjusted for altitude.

Abstract: The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.

Abstract: The present invention relates to a method for controlling or regulating an apparatus for extracorporeally treating blood in an extracorporeal blood circuit while adding citrate and calcium for the purpose of anticoagulation. The apparatus comprises a dispensing device for dispensing a calcium solution into the extracorporeal blood circuit. The method encompasses outputting a signal to the dispensing device for altering a setting of the dispensing device, in which the setting corresponds to or effects an addition of calcium, a calcium dosage, concentration, amount or rate. The method further encompasses defining or altering the signal with regard to a calcium content or a calcium concentration of a substituate solution used in extracorporeally treating the blood, and detecting the range of values of permissible or allowed settings for the calcium introduced or to be introduced into the extracorporeal blood circuit by the dispensing device, particularly its amount, concentration or dosage.

Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolytes but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Abstract: The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.

Abstract: A hemofiltration system and method for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.

Abstract: The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.